Celcuity, based in Minneapolis, employs 55 staff and went public on September 20, 2017. Its lead candidate, gedatolisib, targets specific cancer pathways and is in trials for advanced breast and prostate cancer.
Based on our analysis, Celcuity has received an overvalued rating of 1 out of 5 stars due to several concerning financial metrics.
One critical indicator is the Return on Equity (ROE) ratio, which stands at -45.63, significantly better than the sector average of -74.04. Although this may appear favorable when compared to its peers, a negative ROE indicates that the company is not generating profit from its shareholders' equity, raising concerns about its operational efficiency and profitability.
Another important metric is the Return on Assets (ROA) ratio, which is reported at -33.35, again outpacing the sector's -47.67. A negative ROA suggests that Celcuity is struggling to utilize its assets effectively to generate earnings, indicating potential inefficiencies in asset management.
Additionally, the Net Profit Margin is reported as NaN, which is concerning as it complicates comparisons with the sector average of -138.46. A negative profit margin underscores the company’s challenges in converting revenue into actual profit, suggesting ongoing financial struggles.
While the Price-to-Book (PB) Ratio of 2.52 is lower than the sector average of 2.71, it does not sufficiently offset the negative indicators presented by the other financial metrics.
These factors collectively suggest that Celcuity may not be positioned favorably in the market, leading to its overvalued rating.
This is not a comprehensive overview of our valuation, and should not be viewed as financial advice. Always do your own research before considering an investment.
📡️ Health Care
Overvalued
More Signals
Feature in Progress
This section is under development. Check back soon for updates!